Dobutamine

How to use it (ICU/OT practical)

Indication-led choice: use when you need to increase cardiac output via inotropy (e.g. low-output states) and SVR is not critically low.
- If profound vasodilation/hypotension is dominant, consider adding/using a vasopressor (e.g. noradrenaline) rather than escalating dobutamine alone.
Starting infusion: 2.5–5 micrograms/kg/min, titrate to effect (commonly 2.5–20 micrograms/kg/min).
- Higher doses increase risk of tachyarrhythmias and myocardial ischaemia, aim for the lowest dose achieving perfusion targets.
Targets to titrate against: MAP, urine output, lactate trend, ScvO2/SvO2, echo-derived stroke volume/CO, capillary refill and peripheral perfusion.
Administration: central line preferred (vasoactive infusion), dedicated lumen, use an infusion pump, continuous ECG and BP monitoring.
Weaning: reduce gradually once perfusion stable and underlying cause treated, avoid abrupt cessation in dependent low-output states.

Common clinical scenarios

Acute decompensated heart failure/cardiogenic shock with low output (often with vasopressor support if hypotensive).
Post-cardiac surgery low cardiac output syndrome, RV dysfunction (may help but consider pulmonary vasodilators if PVR high).
- Dobutamine can reduce PVR modestly via beta-2 effects, but tachycardia may worsen RV ischaemia.
Septic shock with myocardial depression (low EF/low stroke volume) after adequate fluid resuscitation and with vasopressor to maintain MAP.
Stress echocardiography (pharmacological stress test).

Drug class and presentation

Synthetic catecholamine, predominantly beta-adrenergic agonist with inotropic effects.
Given IV as continuous infusion, not effective orally (rapid metabolism).

Mechanism of action

Primarily stimulates cardiac beta-1 receptors → ↑ adenylate cyclase → ↑ cAMP → ↑ intracellular Ca2+ availability → ↑ contractility and (to a lesser extent) ↑ HR.
Some beta-2 agonism → peripheral vasodilation (↓ SVR) and mild pulmonary vasodilation (↓ PVR).
Net effect is dose- and patient-dependent, in many patients CO rises with little change or a fall in SVR.

Receptor profile (exam-friendly)

Predominantly beta-1 agonist, also beta-2 agonist, minimal alpha effects at usual doses.
- Clinical translation: strong inotropy with less vasoconstriction than adrenaline/noradrenaline.

Haemodynamic effects

↑ Cardiac output mainly via ↑ stroke volume, HR may increase (less than with adrenaline/isoprenaline but clinically important).
↓ SVR (beta-2) → MAP may fall if CO does not rise sufficiently or if vasoplegia present.
May reduce LV filling pressures by improving forward flow, can worsen dynamic LVOT obstruction (e.g. HOCM) by increasing contractility.
Myocardial oxygen consumption increases (↑ inotropy/chronotropy) → risk of ischaemia in CAD.

Pharmacokinetics

Onset: 1–2 minutes, peak effect within ~10 minutes after dose change.
Half-life: ~2 minutes (very short), hence rapid titratability.
Metabolism: mainly by catechol-O-methyltransferase (COMT) and conjugation, metabolites excreted in urine.

Adverse effects

Tachycardia and tachyarrhythmias (atrial fibrillation, SVT, ventricular ectopy).
Myocardial ischaemia/infarction due to increased oxygen demand and reduced diastolic time (tachycardia).
Hypotension from beta-2 vasodilation, especially in vasoplegia or hypovolaemia.
Electrolyte/metabolic: may cause hypokalaemia (beta-2 mediated intracellular shift), hyperglycaemia (less prominent than adrenaline).
Tolerance/tachyphylaxis can occur with prolonged infusion (beta receptor downregulation).

Contraindications and cautions

Caution in: ischaemic heart disease, tachyarrhythmias, hypertrophic obstructive cardiomyopathy (can worsen LVOT obstruction), severe hypovolaemia (may worsen hypotension).
In atrial fibrillation with rapid ventricular response: may accelerate rate, treat rate and consider alternative strategy.
Beta-blockade: response may be blunted, consider alternative inotrope (e.g. phosphodiesterase inhibitor) depending on context and local practice.

Monitoring and endpoints

Continuous ECG, arterial BP (preferably invasive), clinical perfusion markers, consider echo/CO monitoring in shock states.
Watch for: rising HR, new ectopy, ST changes, falling MAP, worsening lactate, inadequate urine output.

Interactions

MAO inhibitors and tricyclic antidepressants can potentiate catecholamine effects (hypertension/arrhythmias).
Beta-blockers antagonise effects, non-selective beta-blockade may unmask alpha effects (less relevant for dobutamine than for adrenaline).
Halogenated volatile agents increase arrhythmogenicity with catecholamines (clinical relevance depends on dose and patient substrate).

Comparisons (high-yield)

Dobutamine vs dopamine: dobutamine is more predictable inotrope with less tachycardia at equivalent inotropic effect, dopamine has dose-dependent receptor effects and higher arrhythmia risk.
Dobutamine vs adrenaline: adrenaline provides inotropy plus vasoconstriction (alpha) and more metabolic effects (lactate, glucose), dobutamine tends to reduce SVR.
Dobutamine vs noradrenaline: noradrenaline is primarily a vasopressor (alpha) with some beta-1, combine if you need both MAP support and inotropy.

Test yourself…

Describe dobutamine: class, mechanism, and main haemodynamic effects.

Structure your answer: class → receptors → second messenger → haemodynamics.

Class: synthetic catecholamine, IV inotrope.
Receptors: predominantly beta-1, some beta-2, minimal alpha at usual doses.
Mechanism: beta-1 → ↑ cAMP → ↑ intracellular Ca2+ → ↑ contractility (and some ↑ HR).
Haemodynamics: ↑ CO (mainly ↑ SV), HR may rise, ↓ SVR (beta-2) so MAP may fall if CO does not compensate, ↑ myocardial O2 demand.

You are asked: &#039,What dose would you start dobutamine at and how quickly does it work?&#039,

Start 2.5–5 micrograms/kg/min, titrate to effect (commonly up to ~20 micrograms/kg/min).
Onset 1–2 minutes, peak effect within ~10 minutes after a dose change, half-life ~2 minutes.

Explain why dobutamine can cause hypotension in a shocked patient.

Beta-2 mediated vasodilation reduces SVR, if the patient is vasoplegic or underfilled, the fall in SVR may outweigh the CO increase → MAP drops.
Tachycardia can reduce diastolic filling time → stroke volume may not rise as expected, limiting CO response.
Management: correct hypovolaemia, add vasopressor (e.g. noradrenaline), reassess with echo/CO monitoring.

In septic shock, when would you consider adding dobutamine and what would you monitor?

Consider when there is evidence of myocardial depression/low cardiac output despite adequate fluid resuscitation and MAP supported with vasopressor.
Monitor: HR/rhythm, invasive BP, lactate clearance, urine output, ScvO2/SvO2, echo-derived stroke volume/CO, signs of ischaemia.
Be alert to: worsening hypotension (↓ SVR), tachyarrhythmias, rising lactate from ongoing shock (not necessarily drug effect).

List the important adverse effects of dobutamine and how you would mitigate them.

Tachycardia/arrhythmias: titrate slowly, correct electrolytes (K+, Mg2+), treat precipitating factors (pain, hypoxia), consider alternative inotrope if problematic.
Myocardial ischaemia: avoid excessive HR, maintain coronary perfusion pressure, treat anaemia/hypoxia, consider reducing dose or alternative support.
Hypotension: ensure adequate preload, add vasopressor, reassess diagnosis (e.g. tamponade, PE) with echo.

A previous FRCA-style question: &#039,Compare dobutamine with dopamine.&#039,

Receptors: dobutamine mainly beta-1 (plus beta-2), dopamine has dose-dependent dopaminergic/beta/alpha effects (less predictable clinically).
Haemodynamics: dobutamine increases CO with tendency to reduce SVR, dopamine at higher doses increases SVR and HR more variably.
Adverse effects: dopamine associated with more tachyarrhythmias, dobutamine still arrhythmogenic but often preferred for inotropy.
Clinical use: dobutamine for low-output states, dopamine use has declined in many protocols due to arrhythmia risk and lack of renal-protective benefit.

A previous FRCA-style question: &#039,Why might dobutamine be a poor choice in hypertrophic obstructive cardiomyopathy (HOCM)?&#039,

Increased contractility can worsen dynamic LVOT obstruction, tachycardia reduces filling time and LV volume, further increasing obstruction.
Preferred haemodynamic goals in HOCM: maintain preload, avoid tachycardia, maintain/increase afterload (vasoconstrictor), reduce contractility (beta-blocker).

A previous FRCA-style question: &#039,Outline the pharmacokinetics of dobutamine and the implications for infusion changes.&#039,

Very short half-life (~2 minutes) with rapid onset, effects change quickly after dose adjustments.
Allow several minutes (up to ~10 minutes) to assess near-peak response after a change, using haemodynamic and perfusion endpoints.
Because it is rapidly metabolised (COMT), stopping the infusion leads to rapid offset—plan weaning and ensure alternative support if needed.

How would you manage a patient who becomes tachycardic and hypotensive after starting dobutamine?

Immediate assessment: rhythm (ECG), BP (arterial line if possible), signs of ischaemia, volume status, and underlying cause of shock.
Actions: reduce/stop dobutamine if causing harm, correct hypovolaemia, add vasopressor to restore SVR/MAP, treat arrhythmia (rate control/cardioversion as appropriate).
Reassess with bedside echo to exclude tamponade, severe LV dysfunction, RV failure/PE, dynamic LVOT obstruction.

What are the key monitoring requirements and safety considerations for dobutamine infusions in theatre/ICU?

Continuous ECG and frequent BP measurement (ideally invasive), monitor perfusion endpoints (urine output, lactate, mental state, peripheral perfusion).
Central venous access preferred, dedicated lumen, infusion pump, clear labelling and dose in micrograms/kg/min.
Regular review for arrhythmias/ischaemia and for need to add vasopressor if SVR falls.